Literature DB >> 33915080

Principles of signaling pathway modulation for enhancing human naive pluripotency induction.

Jonathan Bayerl1, Muneef Ayyash2, Tom Shani2, Yair Shlomo Manor2, Ohad Gafni2, Rada Massarwa2, Yael Kalma3, Alejandro Aguilera-Castrejon2, Mirie Zerbib2, Hadar Amir3, Daoud Sheban2, Shay Geula2, Nofar Mor2, Leehee Weinberger2, Segev Naveh Tassa2, Vladislav Krupalnik2, Bernardo Oldak2, Nir Livnat2, Shadi Tarazi2, Shadi Tawil2, Emilie Wildschutz2, Shahd Ashouokhi2, Lior Lasman2, Varda Rotter4, Suhair Hanna5, Dalit Ben-Yosef6, Noa Novershtern7, Sergey Viukov2, Jacob H Hanna8.   

Abstract

Isolating human MEK/ERK signaling-independent pluripotent stem cells (PSCs) with naive pluripotency characteristics while maintaining differentiation competence and (epi)genetic integrity remains challenging. Here, we engineer reporter systems that allow the screening for defined conditions that induce molecular and functional features of human naive pluripotency. Synergistic inhibition of WNT/β-CATENIN, protein kinase C (PKC), and SRC signaling consolidates the induction of teratoma-competent naive human PSCs, with the capacity to differentiate into trophoblast stem cells (TSCs) and extraembryonic naive endodermal (nEND) cells in vitro. Divergent signaling and transcriptional requirements for boosting naive pluripotency were found between mouse and human. P53 depletion in naive hPSCs increased their contribution to mouse-human cross-species chimeric embryos upon priming and differentiation. Finally, MEK/ERK inhibition can be substituted with the inhibition of NOTCH/RBPj, which induces alternative naive-like hPSCs with a diminished risk for deleterious global DNA hypomethylation. Our findings set a framework for defining the signaling foundations of human naive pluripotency.
Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cross-species chimerisim; embryonic stem cells; extra-embryonic stem cells; iPSC; naive pluripotency; reprogramming

Year:  2021        PMID: 33915080     DOI: 10.1016/j.stem.2021.04.001

Source DB:  PubMed          Journal:  Cell Stem Cell        ISSN: 1875-9777            Impact factor:   24.633


  16 in total

1.  Rolling back human pluripotent stem cells to an eight-cell embryo-like stage.

Authors:  Md Abdul Mazid; Carl Ward; Zhiwei Luo; Chuanyu Liu; Yunpan Li; Yiwei Lai; Liang Wu; Jinxiu Li; Wenqi Jia; Yu Jiang; Hao Liu; Lixin Fu; Yueli Yang; David P Ibañez; Junjian Lai; Xiaoyu Wei; Juan An; Pengcheng Guo; Yue Yuan; Qiuting Deng; Yang Wang; Ying Liu; Fei Gao; Junwen Wang; Shahriar Zaman; Baoming Qin; Guangming Wu; Patrick H Maxwell; Xun Xu; Longqi Liu; Wenjuan Li; Miguel A Esteban
Journal:  Nature       Date:  2022-03-21       Impact factor: 49.962

2.  Integrated multi-omics reveal polycomb repressive complex 2 restricts human trophoblast induction.

Authors:  Dick W Zijlmans; Irene Talon; Sigrid Verhelst; Adam Bendall; Karlien Van Nerum; Alok Javali; Andrew A Malcolm; Sam S F A van Knippenberg; Laura Biggins; San Kit To; Adrian Janiszewski; Danielle Admiraal; Ruth Knops; Nikky Corthout; Bradley P Balaton; Grigorios Georgolopoulos; Amitesh Panda; Natarajan V Bhanu; Amanda J Collier; Charlene Fabian; Ryan N Allsop; Joel Chappell; Thi Xuan Ai Pham; Michael Oberhuemer; Cankat Ertekin; Lotte Vanheer; Paraskevi Athanasouli; Frederic Lluis; Dieter Deforce; Joop H Jansen; Benjamin A Garcia; Michiel Vermeulen; Nicolas Rivron; Maarten Dhaenens; Hendrik Marks; Peter J Rugg-Gunn; Vincent Pasque
Journal:  Nat Cell Biol       Date:  2022-06-13       Impact factor: 28.213

3.  Cell fate roadmap of human primed-to-naive transition reveals preimplantation cell lineage signatures.

Authors:  Yan Bi; Zhifen Tu; Jianfeng Zhou; Xuehao Zhu; Hong Wang; Shaorong Gao; Yixuan Wang
Journal:  Nat Commun       Date:  2022-06-07       Impact factor: 17.694

Review 4.  New insights into the epitranscriptomic control of pluripotent stem cell fate.

Authors:  Young Hyun Che; Hojae Lee; Yong Jun Kim
Journal:  Exp Mol Med       Date:  2022-10-21       Impact factor: 12.153

5.  KLF17 promotes human naive pluripotency through repressing MAPK3 and ZIC2.

Authors:  Shao-Hua Wang; Jing Hao; Chao Zhang; Fei-Fei Duan; Ya-Tzu Chiu; Ming Shi; Xin Huang; Jihong Yang; Huiqing Cao; Yangming Wang
Journal:  Sci China Life Sci       Date:  2022-04-01       Impact factor: 10.372

6.  KLF17 promotes human naïve pluripotency but is not required for its establishment.

Authors:  Rebecca A Lea; Afshan McCarthy; Stefan Boeing; Todd Fallesen; Kay Elder; Phil Snell; Leila Christie; Sarah Adkins; Valerie Shaikly; Mohamed Taranissi; Kathy K Niakan
Journal:  Development       Date:  2021-11-15       Impact factor: 6.862

7.  TGFβ signalling is required to maintain pluripotency of human naïve pluripotent stem cells.

Authors:  Ludovic Vallier; Daniel Ortmann; Peter J Rugg-Gunn; Anna Osnato; Stephanie Brown; Christel Krueger; Simon Andrews; Amanda J Collier; Shota Nakanoh; Mariana Quiroga Londoño; Brandon T Wesley; Daniele Muraro; A Sophie Brumm; Kathy K Niakan
Journal:  Elife       Date:  2021-08-31       Impact factor: 8.140

8.  Regulation of NANOG and SOX2 expression by activin A and a canonical WNT agonist in bovine embryonic stem cells and blastocysts.

Authors:  Yao Xiao; Froylan Sosa; Pablo J Ross; Kenneth E Diffenderfer; Peter J Hansen
Journal:  Biol Open       Date:  2021-11-29       Impact factor: 2.422

Review 9.  Capturing Pluripotency and Beyond.

Authors:  Chih-Yu Yeh; Wei-Han Huang; Hung-Chi Chen; Yaa-Jyuhn James Meir
Journal:  Cells       Date:  2021-12-16       Impact factor: 6.600

10.  Genome-wide screening identifies Polycomb repressive complex 1.3 as an essential regulator of human naïve pluripotent cell reprogramming.

Authors:  Amanda J Collier; Adam Bendall; Charlene Fabian; Andrew A Malcolm; Katarzyna Tilgner; Claudia I Semprich; Katarzyna Wojdyla; Paola Serena Nisi; Kamal Kishore; Valar Nila Roamio Franklin; Bahar Mirshekar-Syahkal; Clive D'Santos; Kathrin Plath; Kosuke Yusa; Peter J Rugg-Gunn
Journal:  Sci Adv       Date:  2022-03-25       Impact factor: 14.957

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.